Form 4 for CLYM Climb Bio, Inc.
Accepted 2025-07-01 00:00:00 ET · period of report 2025-06-27 · accession 0000950170-25-092284 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DT | 2025-07-01 | 2025-06-27 | CLYM | Brennan Aoife | Pres, CEO, Dir | M - OptEx | — | +68.8K | 68.8K | New | — |
| DT | 2025-07-01 | 2025-06-30 | CLYM | Brennan Aoife | Pres, CEO, Dir | S - Sale+OE | $1.22 | -20.6K | 48.1K | -30% | -$25.2K |
| DT | 2025-07-01 | 2025-06-27 | CLYM | Brennan Aoife | Pres, CEO, Dir | M - OptEx | $0.00 | -68.8K | 206.2K | -25% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-27 | M | A | 68,750 | — | 68,750 | D | — | — | (F1) Each restricted stock unit ("RSU") converted into one share of the Issuer's Common Stock. |
| 2 | Common | Common Stock | 2025-06-30 | S | D | 20,618 | $1.22 | 48,132 | D | — | — | (F3) The price reported is a weighted average price. These shares were sold in multiple transactions at prices within the range of $1.20 to $1.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this Form 4. |
| 3 | Derivative | Restricted Stock Units | 2025-06-27 | M | D | 68,750 | $0.00 | 206,250 | D | — · — to — | 68,750 Common Stock | (F4) Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. (F5) The RSUs were granted on June 27, 2024 (the "Grant Date") and are scheduled to vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the Grant Date, subject to the Reporting Person's continued service. |